NASDAQ:HARP - Harpoon Therapeutics Stock Price, Forecast & News

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics Inc (NASDAQ:HARP) released its earnings results on Monday, August, 5th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.14. The business earned $1.06 million during the quarter, compared to the consensus estimate of $1.22 million. Harpoon Therapeutics had a negative net margin of 1,107.97% and a negative return on equity of 86.88%. View Harpoon Therapeutics' Earnings History.

Harpoon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Harpoon Therapeutics.

7 brokers have issued twelve-month target prices for Harpoon Therapeutics' stock. Their forecasts range from $23.00 to $28.00. On average, they expect Harpoon Therapeutics' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.

Headlines about HARP stock have been trending very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Harpoon Therapeutics.

Harpoon Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 329,000 shares, an increase of 32.1% from the January 15th total of 249,100 shares. Based on an average trading volume of 114,900 shares, the short-interest ratio is presently 2.9 days. Currently, 2.4% of the shares of the company are sold short. View Harpoon Therapeutics' Current Options Chain.

Some companies that are related to Harpoon Therapeutics include Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), Twist Bioscience (TWST), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI), Mesoblast (MESO), Adverum Biotechnologies (ADVM), DBV TECHNOLOGIE/S (DBVT) and Vericel (VCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), NVIDIA (NVDA), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Advanced Micro Devices (AMD), Precision BioSciences (DTIL), Intel (INTC), LogicBio Therapeutics (LOGC) and Universal Display (OLED).

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (3.69%), Fosun International Ltd (0.77%), State Street Corp (0.50%), Renaissance Technologies LLC (0.45%), Geode Capital Management LLC (0.35%) and CIBC World Markets Inc. (0.12%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Institutional Ownership Trends for Harpoon Therapeutics.

HARP stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Fosun International Ltd and Goldman Sachs Group Inc.. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks and Patrick Baeuerle. View Insider Buying and Selling for Harpoon Therapeutics.

HARP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, CIBC World Markets Inc., Russell Investments Group Ltd., Oxford Asset Management LLP, State Street Corp, UBS Group AG and Barclays PLC. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon and Luke Evnin. View Insider Buying and Selling for Harpoon Therapeutics.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HARP stock can currently be purchased for approximately $14.68.

Harpoon Therapeutics has a market capitalization of $361.69 million and generates $4.75 million in revenue each year. The company earns $-27,370,000.00 in net income (profit) each year or ($25.65) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.View Additional Information About Harpoon Therapeutics.

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]